| Released | Contributor | Author | Title | Pages | Price |
| 29-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Onyx Pharmaceuticals has a current Overall Rating of C (Neutral). | 7 |
$25 |
| 29-Nov-2009 | Freedonia Group Inc, The | The Freedonia Group | Freedonia Focus on Cancer Therapies | 23 |
$500 |
| 29-Nov-2009 | Wright Reports |
N/A
| Wright Investors Service Comprehensive Report for Onyx Pharmaceuticals, Inc. | 41 |
$65 |
| 28-Nov-2009 | Stock Traders Daily | Thomas H. Kee Jr. | Trading Report for (ONXX). A detailed Technical Analysis + Trading Plans for Day Trading, Swing Trading, and Long Term proactive investments in (ONXX). | 5 |
$18 |
| 28-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Drug Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards. | 65 |
$20 |
| 27-Nov-2009 | Pechala's Reports | Lubomir Pechala | ONYX PHARMACEUTICALS INC (ONXX=US) 2-weeks forecast | 1 |
$10 |
| 27-Nov-2009 | Pechala's Reports | Frantisek Pechala | ONYX PHARMACEUTICALS INC (ONXX=US) 12-months forecast | 1 |
$15 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Value Graph: ONYX PHARMACEUT -- ONXX | 1 |
$4 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: EXEL , IMGN , MAXY , ONXX , VRNM -- DRUGS | 3 |
$4 |
| 26-Nov-2009 | New Constructs, LLC |
N/A
| ONXX: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings | 19 |
$10 |
1.48% Nasdaq 
Research Reports
